Hims & Hers Health, Inc. (NYSE: HIMS) has issued a formal response to the lawsuit filed by the Federal Trade Commission on July 29, 2026.

The company stated that the legal action disregards extensive evidence provided during the FTC's nearly three-year investigation, ignores existing state laws and telemedicine industry standards, and misinterprets the law in an attempt to manufacture accusations.

According to the company, this is not an enforcement action based on consumer protection but an attempt to generate headlines at their expense. Hims & Hers expressed confidence in its legal position and pledged to vigorously defend against what it described as baseless allegations.

The company affirmed its alignment with the goals of the FTC's newly established healthcare task force, which aims to create a more competitive, innovative, affordable, and higher-quality healthcare system. Since 2017, millions of people have relied on Hims & Hers for convenient and affordable healthcare services, a fact the company takes pride in.

Hims & Hers emphasized that its customers have all the information necessary to make informed decisions about their healthcare services and product use. The company's privacy policy clearly states that customers can choose how their data is used, and information shared between patients and healthcare providers is only used to deliver medical services.

The company concluded by stating that customer trust is the foundation of its business and that it continuously strengthens its processes and systems as it grows.